NBIX logo

Neurocrine Biosciences (NBIX)

Profile

Full Name

Neurocrine Biosciences, Inc.

Ticker Symbol

NBIX

Exchange

NASDAQ

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

IPO

May 23, 1996

Indexes

Not included

Website

http://www.neurocrine.com

Employees

1800

Key Details

Price

$94.89(+4.42%)

Market cap

$9.46B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$2.36B(+24.81% YoY)

Annual EPS

$3.29(+33.20% YoY)

PE ratio

28.84

Next earnings date

May 1, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$94.89
NBIX price is $94.89

30-Day Relative Volume

1.13
NBIX 30-day relative volume is 1.13

Price Performance

Price Most recent change

+4.42%
NBIX price was up +4.42% on Apr 14, 2025

Price YTD change

-30.48%
NBIX price is down -30.48% since January 1st

Price 1-year change

-27.97%
NBIX price is down -27.97% year-on-year

Price 3-year change

-4.41%
NBIX price is down -4.41% over the past 3 years

Price Range

Price All-time high

$157.98
NBIX price is currently -39.94% below its historical high of $157.98

Price 3-year low

$75.25
NBIX price is currently +26.10% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$9.46B
NBIX market capitalization is $9.46 billion

Market cap 3-year change

-0.2%
NBIX market capitalization is down -0.2% over the past 3 years

Market cap All-time high

$15.65B
NBIX market capitalization is currently -39.55% below its historical high of $15.65 billion

Market cap sector rank

92.43%
NBIX market capitalization is higher than 92.43% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-0.87%
NBIX shares outstanding is down -0.87% year-on-year

Shares Outstanding 3-Year Change

+4.4%
NBIX shares outstanding is up +4.4% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.87
NBIX beta is 0.87

200-day SMA

$127.64
NBIX price is currently -25.66% below its 200-day simple moving average

50-day SMA

$113.67
NBIX price is currently -16.52% below its 50-day simple moving average

RSI

37.00
NBIX 14-day relative strength index is 37.00

Volume

1.13
NBIX 30-day relative volume is 1.13

ATR

$4.75
NBIX average true range is $4.75

10-day Historical Volatility

80.46%
NBIX 10-day historical volatility is 80.46%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$2.36B
NBIX annual revenue is $2.36 billion

Revenue Analysts estimate

$2.67B
NBIX annual revenue is currently -11.87% lower than the consensus analysts' forecast

Revenue 1-year change

+24.81%
NBIX annual revenue is up +24.81% year-on-year

Revenue Sector rank

86.23%
NBIX annual revenue is higher than 86.23% of companies in Healthcare sector

EPS

EPS

$3.29
NBIX annual earnings per share is $3.29

EPS Analysts estimate

$6.19
NBIX annual earnings per share is currently -46.83% lower than the consensus analysts' forecast

EPS 1-year change

+33.2%
NBIX annual earnings per share is up +33.2% year-on-year

EPS Sector rank

94.13%
NBIX annual earnings per share is higher than 94.13% of companies in Healthcare sector

Profit

Gross profit

$2.32B
NBIX annual gross profit is $2.32 billion

Gross margin

98.56%
NBIX annual gross profit margin is 98.56%

Operating profit

$583.00M
NBIX annual operating income is $583.00 million

Operating margin

24.75%
NBIX annual operating profit margin is 24.75%

Net income

$341.30M
NBIX annual net profit is $341.30 million

Net margin

14.49%
NBIX annual net profit margin is 14.49%

Expenses

Total expenses

$1.77B
NBIX annual total expenses is $1.77 billion

Operating expenses

$1.74B
NBIX annual total operating expenses is $1.74 billion

Cost of goods sold

$34.00M
NBIX annual cost of goods sold is $34.00 million

Selling, general & administrative expenses

$1.01B
NBIX annual SGA is $1.01 billion

Depreciation and amortization

$27.10M
NBIX annual depreciation & amortization is $27.10 million

Interest expense

$126.60M
NBIX annual interest expense is $126.60 million

Income tax

$144.70M
NBIX annual income tax is $144.70 million

EBIT & EBITDA

EBIT

$583.00M
NBIX annual earnings before interest & taxes is $583.00 million

EBITDA

$583.00M
NBIX annual EBITDA is $583.00 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$3.72B
NBIX annual total assets is $3.72 billion

Non current assets

$1.99B
NBIX annual long term assets is $1.99 billion

Current assets

$1.72B
NBIX annual total current assets is $1.72 billion

Cash and cash equivalents

$233.00M
NBIX annual cash & cash equivalents is $233.00 million

Accounts receivable

$479.10M
NBIX annual accounts receivable is $479.10 million

Inventory

$57.40M
NBIX annual inventory is $57.40 million

Liabilities

Total liabilities

$1.13B
NBIX annual total liabilities is $1.13 billion

Long term liabilities

$621.30M
NBIX annual total long term liabilities is $621.30 million

Current liabilities

$507.70M
NBIX annual total current liabilities is $507.70 million

Accounts payable

$110.00M
NBIX annual accounts payable is $110.00 million

Debt

Total debt

$455.10M
NBIX annual total debt is $455.10 million

Total debt 1-year change

+6.23%
NBIX annual total debt is up +6.23% year-on-year

Long term debt

$455.10M
NBIX annual long term debt is $455.10 million

Short term debt

-
NBIX annual short term debt value is unknown

Equity & Capital

Shareholders equity

$2.59B
NBIX annual stockholders equity is $2.59 billion

Book value

$2.59B
NBIX annual book value is $2.59 billion

Retained earnings

$29.20M
NBIX annual retained earnings is $29.20 million

Working capital

$1.22B
NBIX annual working capital is $1.22 billion

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$595.40M
NBIX annual cash flow from operations is $595.40 million

Cash from operations 1-year change

+52.71%
NBIX annual cash flow from operations is up +52.71% year-on-year

Cash from investing

-$126.80M
NBIX annual cash flow from investing activities is -$126.80 million

Cash from investing 1-year change

+72.85%
NBIX annual cash flow from investing activities is up +72.85% year-on-year

Cash from financing

-$486.70M
NBIX annual cash flow from financing activities is -$486.70 million

Cash from financing 1-year change

-845.33%
NBIX annual cash flow from financing activities is down -845.33% year-on-year

CAPEX

CAPEX

$38.20M
NBIX annual capital expenditures is $38.20 million

CAPEX 1-year change

+34.98%
NBIX annual capital expenditures is up +34.98% year-on-year

Free Cash Flow

Free cash flow

$557.20M
NBIX annual free cash flow is $557.20 million

Free cash flow 1-year change

+54.09%
NBIX annual free cash flow is up +54.09% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

98.56%
NBIX annual gross profit margin is 98.56%

Operating margin

24.75%
NBIX annual operating profit margin is 24.75%

Net margin

14.49%
NBIX annual net profit margin is 14.49%

ROA & ROE

ROA

9.79%
NBIX annual return on assets is 9.79%

ROE

14.16%
NBIX annual return on equity is 14.16%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

28.84
NBIX price to earnings ratio is 28.84

PE ratio Sector rank

58.82%
NBIX price to earnings ratio is higher than 58.82% of companies in Healthcare sector

PB Ratio

PB ratio

3.65
NBIX price to book ratio is 3.65

PB ratio Sector rank

77.12%
NBIX price to book ratio is higher than 77.12% of companies in Healthcare sector

PS Ratio

PS ratio

4.02
NBIX price to sales ratio is 4.02

PS ratio Sector rank

61.41%
NBIX price to sales ratio is higher than 61.41% of companies in Healthcare sector

Enterprise value

Enterprise value

$9.68B
NBIX enterprise value is $9.68 billion

Enterprise value Sector rank

91.74%
NBIX enterprise value is higher than 91.74% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

15.56
NBIX EV/EBITDA is 15.56

EV/EBITDA Sector rank

88.52%
NBIX EV/EBITDA is higher than 88.52% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

3.40
NBIX annual current ratio is 3.40

Quick ratio

3.28
NBIX annual quick ratio is 3.28

Leverage

Debt to equity

0.00
NBIX annual debt to equity ratio is 0.00

Interest coverage ratio

4.61
NBIX annual interest coverage ratio is 4.61

Risk & Stability

Piotroski F-Score

6
NBIX piotroski f-score is 6

Altman Z-Score

6.58
NBIX altman z-score is 6.58

Analyst ratings

Recent major analysts updates

Apr 4, 25 UBS
Buy
Mar 26, 25 JP Morgan
Overweight
Feb 24, 25 HC Wainwright & Co.
Buy
Feb 21, 25 HC Wainwright & Co.
Buy
Feb 10, 25 HC Wainwright & Co.
Buy
Feb 10, 25 Guggenheim
Buy
Feb 7, 25 Wedbush
Outperform
Feb 7, 25 RBC Capital
Sector Perform
Feb 7, 25 Needham
Hold
Feb 7, 25 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

WBA logo
Walgreens Boots Alliance (WBA)
ASND logo
Ascendis Pharma A/S (ASND)
MEDP logo
Medpace Holdings (MEDP)
ATR logo
AptarGroup (ATR)
QGEN logo
Qiagen NV (QGEN)
VTRS logo
Viatris (VTRS)
DOCS logo
Doximity (DOCS)
EXEL logo
Exelixis (EXEL)
GMED logo
Globus Medical (GMED)
  • What is the ticker symbol for Neurocrine Biosciences?
  • Does Neurocrine Biosciences pay dividends?
  • What sector is Neurocrine Biosciences in?
  • What industry is Neurocrine Biosciences in?
  • What country is Neurocrine Biosciences based in?
  • When did Neurocrine Biosciences go public?
  • Is Neurocrine Biosciences in the S&P 500?
  • Is Neurocrine Biosciences in the NASDAQ 100?
  • Is Neurocrine Biosciences in the Dow Jones?
  • When was Neurocrine Biosciences's last earnings report?
  • When does Neurocrine Biosciences report earnings?
  • Should I buy Neurocrine Biosciences stock now?

What is the ticker symbol for Neurocrine Biosciences?

The ticker symbol for Neurocrine Biosciences is NASDAQ:NBIX

Does Neurocrine Biosciences pay dividends?

No, Neurocrine Biosciences does not pay dividends

What sector is Neurocrine Biosciences in?

Neurocrine Biosciences is in the Healthcare sector

What industry is Neurocrine Biosciences in?

Neurocrine Biosciences is in the Drug Manufacturers - Specialty & Generic industry

What country is Neurocrine Biosciences based in?

Neurocrine Biosciences is headquartered in United States

When did Neurocrine Biosciences go public?

Neurocrine Biosciences's initial public offering (IPO) was on May 23, 1996

Is Neurocrine Biosciences in the S&P 500?

No, Neurocrine Biosciences is not included in the S&P 500 index

Is Neurocrine Biosciences in the NASDAQ 100?

No, Neurocrine Biosciences is not included in the NASDAQ 100 index

Is Neurocrine Biosciences in the Dow Jones?

No, Neurocrine Biosciences is not included in the Dow Jones index

When was Neurocrine Biosciences's last earnings report?

Neurocrine Biosciences's most recent earnings report was on Feb 6, 2025

When does Neurocrine Biosciences report earnings?

The next expected earnings date for Neurocrine Biosciences is May 1, 2025

Should I buy Neurocrine Biosciences stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page